Gene Therapy for Meningeal Carcinomatosis 
consultation between the investigator, the IRB, and the sponsor. 
If the consensus is to revise the current protocol, a formal List of Changes will accompany 
the amended protocol and these will be submitted to the FDA, the IRB, and other committees as 
required. 
Both the sponsor and the investigator reserve the right to terminate the study at any time. If 
this becomes necessary, appropriate procedures for continuing the long-term follow-up requested 
by the regulatory agencies will be arranged after review and approval by both parties. 
15.0 Publication of Data/Protection of Company Secrets 
The investigator will agree to inform the sponsor of all study results. Any manuscript, 
abstract, or presentation will be made available to the sponsor and all participating study 
investigators for review prior to submission of manuscripts, abstracts, or scientific meetings. This 
will allow the sponsor to protect proprietary information and to provide comment based on 
information that may not yet be available to the investigator. Authorship will be determined by 
mutual agreement 
Recombinant DNA Research, Volume 18 
[611] 
